RL71, a second-generation curcumin analog, induces apoptosis and downregulates Akt in ER-negative breast cancer cells

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 1119-1127

  Yadav, Babasaheb ^a   Taurin, Sebastien ^a   Larsen, Lesley ^a   Rosengren, Rhonda J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Angiogenesis; Apoptosis; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN KINASE B; PROTEIN P27; RL 71; RL71; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG BLOOD LEVEL; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL MOVEMENT; CURCUMIN; DOWN-REGULATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84865005159     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1521     Document Type: Article

References (50)

1. Parl FF, Schmidt BP, Dupont WD and Wagner RK: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54: 2237-2242, 1984.
2. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C and Gerald WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25: 3994-4008, 2006.
3. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007.
4. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
5. Kaplan HG and Malmgren JA: Impact of triple negative phenotype on breast cancer prognosis. Breast J 14: 456-463, 2008.
6. Anand P, Thomas Sherin G, Kunnumakkara Ajaikumar B, et al: Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76: 1590-1611, 2008.
7. Cheng A-L, Hsu C-H, Lin J-K, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900, 2001.
8. Inano H, Onoda M, Inafuku N, et al: Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. Carcinogenesis 20: 1011-1018, 1999.
9. Pereira MA, Grubbs CJ, Barnes LH, et al: Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 17: 1305-1311, 1996.
10. Schaaf C, Shan B, Buchfelder M, et al: Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo. Endocr Relat Cancer 16: 1339-1350, 2009.
11. Singletary K, MacDonald C, Wallig M and Fisher C: Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett 103: 137-141, 1996.
12. Chiu T-L and Su C-C: Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-κBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med 23: 469-475, 2009.
13. Kang HJ, Lee SH, Price JE and Kim LS: Curcumin suppresses the paclitaxel-induced nuclear factor-κB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J 15: 223-229, 2009.
14. Liu Q, Loo WTY, Sze SCW and Tong Y: Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFκB, cyclinD and MMP-1 transcription. Phytomed 16: 916-922, 2009.
15. Prasad CP, Rath G, Mathur S, Bhatnagar D and Ralhan R: Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chem Biol Interact 181: 263-271, 2009.
16. Rowe DL, Ozbay T, O'Regan RM and Nahta R: Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer Basic Clin Res 3: 61-75, 2009.
17. Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP and Rosengren RJ: The combination of epigallocatechin gallate and curcumin suppresses ERalpha-breast cancer cell growth in vitro and in vivo. Int J Cancer 122: 1966-1971, 2008.
18. Wu X and Wu K: Antiproliferative effect of curcumin on human breast cancer of MCF-7 cells. Di-San Junyi Daxue Xuebao 28: 1870-1872, 2006.
19. Liang G, Shao L, Wang Y, et al: Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem 17: 2623-2631, 2009.
20. Markaverich BM, Schauweker TH, Gregory RR, Varma M, Kittrell FS, Medina D and Varma RS: Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidene-cyclohexanones. Cancer Res 52: 2482-2488, 1992.
21. Adams BK, Ferstl EM, Davis MC, et al: Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 12: 3871-3883, 2004.
22. Adams Brian K, Cai J, Armstrong J, et al: EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16: 263-275, 2005.
23. Yadav B, Taurin S, Rosengren RJ, Schumacher M, Diederich M, Somers-Edgar TJ and Larsen L: Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin. Bioorg Med Chem 18: 6701-6707, 2010.
24. Skehan P, Storeng R, Scudiero D, et al: New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
25. Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA and Rosengren RJ: Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Invest New Drugs 29: 87-97, 2011.
26. Stuart EC and Rosengren RJ: The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells. Life Sci 82: 943-948, 2008.
27. Wang SC and Hung MC: HER2 overexpression and cancer targeting. Semin Oncol 28: 115-124, 2001.
28. Hsieh WT, Huang KY, Lin HY and Chung JG: Physalis angulata induced G2/M phase arrest in human breast cancer cells. Food Chem Toxicol 44: 974-983, 2006.
29. Hsu JD, Kao SH, Ou TT, Chen YJ, Li YJ and Wang CJ: Gallic acid induces G2/M phase arrest of breast cancer cell MCF-7 through stabilization of p27(Kip1) attributed to disruption of p27(Kip1)/Skp2 complex. J Agric Food Chem 59: 1996-2003, 2011.
30. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH and Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239-256, 2002.
31. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849, 2004.
32. Liu B, Han M, Sun RH, Wang JJ, Zhang YP, Zhang DQ and Wen JK: ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activation. Breast Cancer Res 12: R9, 2010.
33. Kuo PL, Chen CY and Hsu YL: Isoobtusilactone a induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells. Cancer Res 67: 7406-7420, 2007.
34. Collett GP and Campbell FC: Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25: 2183-2189, 2004.
35. Weir NM, Selvendiran K, Kutala VK, et al: Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 6: 178-184, 2007.
36. Eto I: Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells. Cancer Cell Int 6: 20, 2006.
37. Dillon RL, White DE and Muller WJ: The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26: 1338-1345, 2007.
38. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
39. Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-Burow BM, Beckman BS and McLachlan JA: PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun 271: 342-345, 2000.
40. Gong L, Li Y, Nedeljkovic-Kurepa A and Sarkar FH: Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22: 4702-4709, 2003.
41. Barkett M and Gilmore TD: Control of apoptosis by Rel/NF-kappaB t ranscription f actors. O ncogene 18: 6 910-6924, 1999.
42. Lauder A, Castellanos A and Weston K: c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of T cells and is required for PKB-mediated protection from apoptosis. Mol Cell Biol 21: 5797-5805, 2001.
43. Shehzad A, Wahid F and Lee YS: Curcumin in cancer chemo-prevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm 343: 489-499, 2010.
44. Dhandapani KM, Mahesh VB and Brann DW: Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102: 522-538, 2007.
45. Kasinski AL, Du Y, Thomas SL, et al: Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 74: 654-661, 2008.
46. Al-Hujaily EM, Mohamed AG, Al-Sharif I, et al: PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on Er-negative cells. Breast Cancer Res Treat 128: 97-107, 2010.
47. Hutzen B, Friedman L, Sobo M, et al: Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int J Oncol 35: 867-872, 2009.
48. Kumar AP, Garcia GE, Ghosh R, Rajnarayanan RV, Alworth WL and Slaga TJ: 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management. Neoplasia 5: 255-266, 2003.
49. Lin L, Hutzen B, Ball S, et al: New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci 100: 1719-1727, 2009.
50. Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB: Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818, 2007.